Key result
Total artificial heart implantation as a bridge to transplantation resulted in 67% of implanted patients and 94% of transplanted patients being discharged alive in the most recent series.
Why the study?
Does total artificial heart (TAH) implantation provide a viable bridge to transplantation in selected patients?
Does total artificial heart (TAH) implantation provide a viable bridge to transplantation in selected patients?
Answers are grounded in this paper and cite their sources.
Total artificial heart implantation has evolved into a viable therapeutic option as a bridge to transplantation for selected patients inappropriate for LVADs, with improving survival and decreasing complication rates.
Interest in development of mechanical cardiac support has grown out of the realization of the enormous impact of heart failure‐related mortality, the limited potential to provide cardiac transplantation (approximately 2000 patients/year in the USA), and the long waiting period required, even in appropriately selected patients. Both left ventricular assist devices (LVADs) and total artificial hearts (TAHs) have been developed to assist in addressing these needs. This review focuses on TAH development. The first bridging TAH was implanted in 1969, and the first permanent device in 1982 with a patient survival of 112 days. Since that time, evolution of device design and manufacture, patient selection, and ancillary therapies have occurred. Worldwide clinical application now spans 27 years and includes experience with TAH implantation in 311 patients, with eight different pneumatically driven devices implanted either as permanent devices (N = 5) or as temporary, bridging therapy to transplantation (N = 306), with all but four implanted after 1984. Utah‐developed TAHs represent the largest source of this experience (N = 287). In the earlier (Symbion manufactured) TAH series (N = 204, 1985–1992), 42% of implanted patients and 59% of transplanted patients were discharged alive from the hospital, and average support time was 24 days. In the current (Cardio West manufactured) series (N = 78, 1993–1996), 67% of implanted patients and 94% of transplanted patients were discharged alive, and average support time is 30 days. Of transplanted and discharged patients, 98% remain alive. With improvements in device design and manufacture, as well as anticoagulant regimens, the incidence of stroke with long‐term deficits has decreased from 3 out of 7 in 1984‐1985 to 1 out of 61 in 1988, with no permanent deficits since then. Infection rates have also decreased. Only one implanted patient died of TAH mechanical failure (an early experience). Based on this evolving experience, use of the TAH as a bridge to transplantation in selected patients who are not appropriate for an LVAD has become a viable current therapeutic option. Further TAH development and application is anticipated.
No takes yet. Share an insight, caveat, or question.
Olsen et al. (1997) conducted a review in Heart failure (n=311). Total Artificial Heart (TAH) was evaluated on Survival to hospital discharge. Total artificial heart implantation as a bridge to transplantation resulted in 67% of implanted patients and 94% of transplanted patients being discharged alive in the most recent series.
Synapse has enriched 10 related papers. Consider them for comparative context: